Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

National City, California 91950


Purpose:

The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.


Criteria:

Inclusion criteria: - If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception. - Diagnosis of Schizophrenia - Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study. Exclusion criteria: - Patients who are currently taking or have taken antidepressant medication in the last month prior. - Patients who are or have been suicidal or homicidal in the last 6 months. - Patients with a history of autistic disorder or another pervasive developmental disorder - Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition


NCT ID:

NCT00071747


Primary Contact:

Study Director
GSK Clinical Trials
GlaxoSmithKline


Backup Contact:

N/A


Location Contact:

National City, California 91950
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.